Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is set to announce its financial results for the fourth quarter and full year of 2025 after market close on February 18, 2026. In conjunction with the earnings release, the company will hold a live conference call and webcast at 5:00 p.m. U.S. Eastern Standard Time to discuss the results and provide a comprehensive business update. Interested stakeholders can access materials related to the announcement on the Investor Relations section of the Bausch Health website prior to the conference call.

Bausch Health, headquartered in Laval, Quebec, is a prominent global diversified pharmaceutical company with a mission to enhance health outcomes through continuous innovation and development of healthcare solutions. The company operates in multiple therapeutic areas, including gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health, primarily through its controlling interest in Bausch + Lomb.

With a focus on being a globally integrated healthcare entity, Bausch Health aims to establish trust and value among its patients, healthcare professionals, employees, and investors. The company is committed to delivering a wide array of healthcare products that enrich lives and deliver better health care outcomes.

Analysts and investors will be closely watching the upcoming announcement for insights into the company’s financial performance, operational achievements, and strategic direction moving forward. For more information about the company’s financials or to participate in the conference call, investors can reach out via the provided contact information. Bausch Health looks forward to sharing its progress with its stakeholders and the broader market during this pivotal update.

Bausch Health Companies Inc. (NYSE:BHC) is scheduled to announce its fourth-quarter and full-year financial results for 2025 on February 18, 2026. This upcoming report provides investors with a crucial opportunity to assess the company's financial health and strategic direction, particularly as it navigates challenges within the pharmaceutical and healthcare sectors.

As we approach this earnings call, it is important for investors to consider several key factors. Firstly, Bausch Health has historically faced scrutiny regarding its debt levels and regulatory challenges related to its diverse portfolio, which includes offerings in gastroenterology, dermatology, eye health, and more. This diverse product range can be a double-edged sword; while it offers multiple revenue streams, it also complicates the company’s overall management and strategy.

Investors should pay close attention to guidance provided during the earnings call. Analysts will be looking for insights into revenue growth, EBITDA margins, and specific performance metrics from its core divisions. Additionally, commentary on recent product launches or innovations, particularly from the Bausch + Lomb unit, will be critical, as this segment remains a pivotal growth driver.

Moreover, industry trends, such as the increasing demand for telehealth and ongoing shifts in patient care paradigms, could influence Bausch's performance. If the company can effectively leverage these trends, particularly in the wake of ongoing healthcare transformations post-pandemic, it could present a favorable outlook.

As always, potential investors should weigh Bausch Health’s performance against its peers and consider broader market conditions. With its upcoming earnings report and a strategic focus on enhancing healthcare outcomes, Bausch Health may be positioned for a positive shift in investor sentiment if it demonstrates progress in its operational metrics and debt management.